[
    {
        "title": "European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) - Yahoo Finance",
        "description": "European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)  Yahoo Finance",
        "published date": "Tue, 29 Aug 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiYWh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9ldXJvcGVhbi1jb21taXNzaW9uLWFwcHJvdmVzLWtleXRydWRhLXBlbWJyb2xpenVtYWItMTA1MDAwODAwLmh0bWzSAWlodHRwczovL2ZpbmFuY2UueWFob28uY29tL2FtcGh0bWwvbmV3cy9ldXJvcGVhbi1jb21taXNzaW9uLWFwcHJvdmVzLWtleXRydWRhLXBlbWJyb2xpenVtYWItMTA1MDAwODAwLmh0bWw?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    }
]